ESTRO Multidisciplinary Management of Breast Cancer 2017

Relative and Absolute Risk Reduction

Relative Risk Reduction by Therapy: 50 %

Absolute Risk 50 % Individual Benefit 25 % Absolute Risk 10 % Individual Benefit 5 %

Absolute Benefit: Number Needed To Treat

03/01/13